Trials & Filings

OncoMed Hits Dose Escalation Milestone

Triggers $15 mil. payment from Bayer

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

OncoMed Pharmaceuticals has earned a $15 million milestone payment from Bayer Pharma AG related to achieving a dose escalation milestone in the Phase Ia clinical trial of OMP-54F28 (Fzd8-Fc). OMP-54F28 is an antagonist of the Wnt pathway, a key cancer stem cell pathway. The Phase Ia trial of OMP-54F28 is an open-label dose escalation study in patients with advanced solid tumors. It is designed to assess OMP-54F28 for safety, immunogenicity, pharmacokinetics, biomarkers, and initial signals of e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters